Titre : Galactose

Galactose : Questions médicales fréquentes

Termes MeSH sélectionnés :

Problem Solving
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Galactose : Questions médicales les plus fréquentes", "headline": "Galactose : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Galactose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-04", "dateModified": "2025-03-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Galactose" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hexose", "url": "https://questionsmedicales.fr/mesh/D006601", "about": { "@type": "MedicalCondition", "name": "Hexose", "code": { "@type": "MedicalCode", "code": "D006601", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D09.947.875.359" } } }, "about": { "@type": "MedicalCondition", "name": "Galactose", "alternateName": "Galactose", "code": { "@type": "MedicalCode", "code": "D005690", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Tilo Biedermann", "url": "https://questionsmedicales.fr/author/Tilo%20Biedermann", "affiliation": { "@type": "Organization", "name": "Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany." } }, { "@type": "Person", "name": "Eva Morava", "url": "https://questionsmedicales.fr/author/Eva%20Morava", "affiliation": { "@type": "Organization", "name": "Department of Paediatrics and Metabolic Center, University Hospitals Leuven, Leuven, Belgium. peter.witters@uzleuven.be." } }, { "@type": "Person", "name": "Scott P Commins", "url": "https://questionsmedicales.fr/author/Scott%20P%20Commins", "affiliation": { "@type": "Organization", "name": "Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, North Carolina." } }, { "@type": "Person", "name": "Marianne van Hage", "url": "https://questionsmedicales.fr/author/Marianne%20van%20Hage", "affiliation": { "@type": "Organization", "name": "Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and University Hospital, Stockholm, Sweden." } }, { "@type": "Person", "name": "Michael Levin", "url": "https://questionsmedicales.fr/author/Michael%20Levin", "affiliation": { "@type": "Organization", "name": "Division of Paediatric Allergy, University of Cape Town, Cape Town, South Africa. Electronic address: Michael.levin@uct.ac.za." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Importance of most frequent needs of the disabled in shaping areas of support in public health. Part. II. Disability as a consequence of dysfunction in the state of health disrupting daily functioning based on selected health and socio-demographic characteristics - interdisciplinary problems in the domain of public health.", "datePublished": "2022-12-27", "url": "https://questionsmedicales.fr/article/36583315", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.26444/aaem/158547" } }, { "@type": "ScholarlyArticle", "name": "The Strengths and Difficulties Questionnaire Is of Clinical Significance Regarding Emotional and Behavioral Problems in 7-Year-Old Children With Familial Risk of Schizophrenia or Bipolar Disorder and Population-Based Controls the Danish High Risk and Resilience Study-VIA 7; A Population-Based Cohort Study.", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35693960", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpsyt.2022.861219" } }, { "@type": "ScholarlyArticle", "name": "Study protocol for an adaptive, multi-arm, multi-stage (MAMS) randomised controlled trial of brief remotely delivered psychosocial interventions for people with serious mental health problems who have experienced a recent suicidal crisis: Remote Approaches to Psychosocial Intervention Delivery (RAPID).", "datePublished": "2024-07-06", "url": "https://questionsmedicales.fr/article/38971788", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13063-024-08293-5" } }, { "@type": "ScholarlyArticle", "name": "A randomised controlled trial to compare clinical and cost-effectiveness of an online parent-led treatment for child anxiety problems with usual care in the context of COVID-19 delivered in Child and Adolescent Mental Health Services in the UK (Co-CAT): a study protocol for a randomised controlled trial.", "datePublished": "2022-11-16", "url": "https://questionsmedicales.fr/article/36384704", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13063-022-06833-5" } }, { "@type": "ScholarlyArticle", "name": "Statistical analysis plans for two randomised controlled trials of the Narrative Experiences Online (NEON) Intervention: impact of receiving recorded mental health recovery narratives on quality of life in people experiencing psychosis (NEON) and people experiencing non-psychosis mental health problems (NEON-O).", "datePublished": "2023-05-20", "url": "https://questionsmedicales.fr/article/37210551", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13063-023-07246-8" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Glucides", "item": "https://questionsmedicales.fr/mesh/D002241" }, { "@type": "ListItem", "position": 3, "name": "Sucres", "item": "https://questionsmedicales.fr/mesh/D000073893" }, { "@type": "ListItem", "position": 4, "name": "Oses", "item": "https://questionsmedicales.fr/mesh/D009005" }, { "@type": "ListItem", "position": 5, "name": "Hexose", "item": "https://questionsmedicales.fr/mesh/D006601" }, { "@type": "ListItem", "position": 6, "name": "Galactose", "item": "https://questionsmedicales.fr/mesh/D005690" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Galactose - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Galactose", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Galactose", "description": "Comment diagnostiquer une intolérance à la galactose ?\nQuels tests sont utilisés pour détecter la galactosémie ?\nQuels symptômes indiquent un problème avec la galactose ?\nComment évaluer le métabolisme de la galactose ?\nQuel rôle joue l'enzyme galactose-1-phosphate uridyltransférase ?", "url": "https://questionsmedicales.fr/mesh/D005690?mesh_terms=Problem+Solving&page=782#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Galactose", "description": "Quels sont les symptômes d'une galactosémie ?\nComment se manifeste l'intolérance au galactose ?\nQuels signes indiquent une surcharge de galactose ?\nLa galactose peut-elle causer des problèmes oculaires ?\nQuels symptômes neurologiques sont associés à la galactosémie ?", "url": "https://questionsmedicales.fr/mesh/D005690?mesh_terms=Problem+Solving&page=782#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Galactose", "description": "Comment prévenir la galactosémie chez les nouveau-nés ?\nLes femmes enceintes doivent-elles se soucier de la galactose ?\nQuels aliments éviter pour prévenir l'intolérance au galactose ?\nLe dépistage génétique est-il utile pour la galactosémie ?\nComment sensibiliser à la galactosémie ?", "url": "https://questionsmedicales.fr/mesh/D005690?mesh_terms=Problem+Solving&page=782#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Galactose", "description": "Quel est le traitement principal de la galactosémie ?\nPeut-on utiliser des suppléments pour la galactosémie ?\nComment gérer l'intolérance au galactose ?\nY a-t-il des médicaments pour traiter la galactosémie ?\nComment surveiller l'évolution d'une galactosémie ?", "url": "https://questionsmedicales.fr/mesh/D005690?mesh_terms=Problem+Solving&page=782#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Galactose", "description": "Quelles complications peuvent survenir avec la galactosémie ?\nLa galactosémie peut-elle affecter le développement physique ?\nQuels risques neurologiques sont associés à la galactosémie ?\nComment la galactosémie affecte-t-elle le foie ?\nY a-t-il des complications à long terme de la galactosémie ?", "url": "https://questionsmedicales.fr/mesh/D005690?mesh_terms=Problem+Solving&page=782#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Galactose", "description": "Quels sont les facteurs de risque de la galactosémie ?\nLa consanguinité augmente-t-elle le risque de galactosémie ?\nLes femmes porteuses de gènes de galactosémie doivent-elles s'inquiéter ?\nLes populations spécifiques sont-elles plus à risque ?\nComment les tests génétiques aident-ils à évaluer le risque ?", "url": "https://questionsmedicales.fr/mesh/D005690?mesh_terms=Problem+Solving&page=782#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intolérance à la galactose ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un test de tolérance au galactose et des analyses sanguines peuvent confirmer l'intolérance." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter la galactosémie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des dosages de galactose dans le sang sont utilisés." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec la galactose ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la diarrhée, les vomissements et la jaunisse peuvent indiquer un problème." } }, { "@type": "Question", "name": "Comment évaluer le métabolisme de la galactose ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de métabolisme et des analyses enzymatiques peuvent évaluer la dégradation de la galactose." } }, { "@type": "Question", "name": "Quel rôle joue l'enzyme galactose-1-phosphate uridyltransférase ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Cette enzyme est cruciale pour le métabolisme de la galactose et son absence cause des troubles." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une galactosémie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent vomissements, diarrhée, jaunisse et retard de croissance." } }, { "@type": "Question", "name": "Comment se manifeste l'intolérance au galactose ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle se manifeste par des douleurs abdominales, des ballonnements et des diarrhées après ingestion." } }, { "@type": "Question", "name": "Quels signes indiquent une surcharge de galactose ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme la fatigue, des troubles neurologiques et des problèmes hépatiques peuvent apparaître." } }, { "@type": "Question", "name": "La galactose peut-elle causer des problèmes oculaires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une accumulation de galactose peut entraîner des cataractes et d'autres problèmes oculaires." } }, { "@type": "Question", "name": "Quels symptômes neurologiques sont associés à la galactosémie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles du développement, des convulsions et des retards mentaux peuvent survenir." } }, { "@type": "Question", "name": "Comment prévenir la galactosémie chez les nouveau-nés ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage néonatal permet de détecter la galactosémie et d'initier un traitement précoce." } }, { "@type": "Question", "name": "Les femmes enceintes doivent-elles se soucier de la galactose ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles doivent surveiller leur consommation de galactose, surtout si des antécédents familiaux existent." } }, { "@type": "Question", "name": "Quels aliments éviter pour prévenir l'intolérance au galactose ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Évitez les produits laitiers, les légumineuses et certains fruits comme les cerises." } }, { "@type": "Question", "name": "Le dépistage génétique est-il utile pour la galactosémie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut identifier les porteurs et les personnes à risque de développer la maladie." } }, { "@type": "Question", "name": "Comment sensibiliser à la galactosémie ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des campagnes d'information et des ressources éducatives peuvent aider à sensibiliser le public." } }, { "@type": "Question", "name": "Quel est le traitement principal de la galactosémie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement consiste à suivre un régime strict sans galactose, excluant les produits laitiers." } }, { "@type": "Question", "name": "Peut-on utiliser des suppléments pour la galactosémie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments de calcium et de vitamine D peuvent être nécessaires en raison d'un régime restrictif." } }, { "@type": "Question", "name": "Comment gérer l'intolérance au galactose ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les aliments contenant du galactose et consulter un diététicien pour un suivi." } }, { "@type": "Question", "name": "Y a-t-il des médicaments pour traiter la galactosémie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de médicaments spécifiques, le régime est le traitement principal." } }, { "@type": "Question", "name": "Comment surveiller l'évolution d'une galactosémie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des contrôles réguliers des niveaux de galactose et des évaluations cliniques sont nécessaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la galactosémie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des problèmes hépatiques, des cataractes et des troubles neurologiques." } }, { "@type": "Question", "name": "La galactosémie peut-elle affecter le développement physique ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner un retard de croissance et des problèmes de développement physique." } }, { "@type": "Question", "name": "Quels risques neurologiques sont associés à la galactosémie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des convulsions, des retards mentaux et des troubles du comportement peuvent survenir." } }, { "@type": "Question", "name": "Comment la galactosémie affecte-t-elle le foie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer une hépatomégalie et des lésions hépatiques dues à l'accumulation de galactose." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme de la galactosémie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme incluent des troubles cognitifs et des problèmes de vision." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de la galactosémie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de galactosémie et certaines mutations génétiques augmentent le risque." } }, { "@type": "Question", "name": "La consanguinité augmente-t-elle le risque de galactosémie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la consanguinité peut augmenter le risque de transmission de la galactosémie." } }, { "@type": "Question", "name": "Les femmes porteuses de gènes de galactosémie doivent-elles s'inquiéter ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent transmettre le gène à leurs enfants, augmentant le risque de la maladie." } }, { "@type": "Question", "name": "Les populations spécifiques sont-elles plus à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines populations, comme les Ashkénazes, ont un risque plus élevé de galactosémie." } }, { "@type": "Question", "name": "Comment les tests génétiques aident-ils à évaluer le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les tests génétiques peuvent identifier les porteurs et évaluer le risque de transmission." } } ] } ] }

Sources (7816 au total)

Importance of most frequent needs of the disabled in shaping areas of support in public health. Part. II. Disability as a consequence of dysfunction in the state of health disrupting daily functioning based on selected health and socio-demographic characteristics - interdisciplinary problems in the domain of public health.

The disabled are a group with heterogeneous structure of causes and needs. Assessment of these causes and needs requires prospective studies in order to use the results within public health actions, i... The examined population were 676 disabled aged from 19-98, including 56.4% of females, and 43,6% of males; rural inhabitants constituted 38.0%. The study was conducted by the method of purposive sampl... The most frequently occurring problems were material difficulties, lack of rehabilitation in the place of residence, hindered access to a physician, difficulties with settling official matters, loneli... The majority of the problems hindering daily life of the disabled fell within social rather than medical categories. Age, level of education, degree of disability, legal status, and material standard ...

The Strengths and Difficulties Questionnaire Is of Clinical Significance Regarding Emotional and Behavioral Problems in 7-Year-Old Children With Familial Risk of Schizophrenia or Bipolar Disorder and Population-Based Controls the Danish High Risk and Resilience Study-VIA 7; A Population-Based Cohort Study.

Children born to parents with severe mental illness are at increased risk of mental and behavioral difficulties during childhood. We aimed to investigate the occurrence of clinically significant behav... By means of the Danish National Registers, we established a cohort of 522 7-year old children stratified by familial high risk for schizophrenia spectrum disorder (... Children with familial high risk of schizophrenia spectrum disorder or bipolar disorder have a significantly increased risk (OR = 3.8 and 2.3) of suffering clinically significant behavioral difficulti...

Study protocol for an adaptive, multi-arm, multi-stage (MAMS) randomised controlled trial of brief remotely delivered psychosocial interventions for people with serious mental health problems who have experienced a recent suicidal crisis: Remote Approaches to Psychosocial Intervention Delivery (RAPID).

People with serious mental health problems (SMHP) are more likely to be admitted to psychiatric hospital following contact with crisis services. Admissions can have significant personal costs, be trau... A multi-stage, multi-arm (MAMS) randomised controlled trial (RCT) with four arms conducted over two stages to determine the clinical and cost effectiveness of three psychosocial treatments, compared t... There is a need for evidence-based interventions to reduce psychiatric admissions, via reduction of suicidality. Our focus on remote delivery of established brief psychosocial interventions, utilisati... ISRCTN33079589. Registered on June 20, 2022....

A randomised controlled trial to compare clinical and cost-effectiveness of an online parent-led treatment for child anxiety problems with usual care in the context of COVID-19 delivered in Child and Adolescent Mental Health Services in the UK (Co-CAT): a study protocol for a randomised controlled trial.

In the context of COVID-19, NHS Child and Adolescent Mental Health Services (CAMHS) and other children's mental health services have faced major challenges in providing psychological treatments that (... We will conduct a two-arm, multi-site, randomised controlled non-inferiority trial to evaluate the clinical and cost-effectiveness of OSI with therapist support compared to CAMHS and other child menta... If non-inferiority is shown, the research will provide (1) a solution for efficient psychological treatment for child anxiety disorders while social distancing (for the COVID-19 context and future pan... ISRCTN ISRCTN12890382 . Registered prospectively on 23 October 2020....

Statistical analysis plans for two randomised controlled trials of the Narrative Experiences Online (NEON) Intervention: impact of receiving recorded mental health recovery narratives on quality of life in people experiencing psychosis (NEON) and people experiencing non-psychosis mental health problems (NEON-O).

Mental health recovery narratives are a first-hand account of an individual's recovery from mental health distress, access to narratives can aid recovery. The NEON Intervention is a web-application pr... The NEON Intervention is assessed in two trial populations, one for people with experience of psychosis in the last 5 years, and mental health distress in the last six months (NEON Trial) and one for ... The primary outcome is the mean score of subjective items on the Manchester Short Assessment of Quality-of-Life questionnaire (MANSA) at 52 weeks. Secondary outcomes are scores from the Herth Hope Ind... This manuscript is the statistical analysis plan (SAP) for the NEON trials. Any post hoc analysis, such as those requested by journal reviewers will be clearly labelled as such in the final trial repo...

A cluster randomised, 16-week, parallel-group multicentre trial to compare the effectiveness of a digital school-based cognitive behavioural resilience/wellbeing-building intervention targeting emotional and behavioural problems in vulnerable Year 4 primary school children in whole classes, to the usual school curriculum: a study protocol to the "CUES for Schools" trial.

Around 10% of school-aged children experience mental health difficulties. Many more are 'vulnerable': experiencing emotional and/or behavioural problems reaching clinical levels, and thus at greatest ... The "CUES for Schools" study is a multicentre cluster randomised controlled trial in primary schools in south east England. Schools will be randomised to receive the usual school curriculum, or the CU... The study will show whether CUES for schools is more effective than the usual curriculum in reducing emotional and behavioural problems in vulnerable Year 4 children, and thus reducing the risk of men... Trial Registration ISRCTN11445338. Registered on September 12, 2022....